FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308523224> ?p ?o ?g. }

• W4308523224 endingPage "2204" @default.
• W4308523224 startingPage "2204" @default.
• W4308523224 abstract "Several drugs now employed in cancer therapy were discovered as a result of anticancer drug research based on natural products. Here, we reported the in vitro antioxidant and anticancer activity followed by in silico anticancer and estrogen-like activity of Psidium guajava L. essential oil against ER-α receptors which lead to potential inhibitory action against breast cancer pathways. Methods: The bioactive compounds in guava essential oil were screened using gas chromatography–mass spectrometry (GC-MS). Similarly, the antioxidant properties of the extracted oil were evaluated using 2,2-Diphenyl-1-picrylhydrazyl scavenging assay. Furthermore, the in vitro anticancer activity of guava oil was observed through the MTT assay and an in silico molecular docking experiment was also carried out to ensure that they fit into the estrogen receptors (ERs) and possess anticancer potential. Results: The GC–MS profile of the essential oil revealed the presence of 17 chemicals, with limonene (51.3%), eucalyptol (21.3%), caryophyllene oxide (6.2%), caryophyllene (5.6%), and nerolidol (4.5%) occupying more than one-third of the chromatographic spectrum zone. Guava leaves’ essential oil (EO) inhibited DPPH (2,2-diphenyl-1-picrylhydrazyl) radicals and exhibited concentration dependent free radical scavenging activity, acting as a potent antioxidant with an IC50 value of 29.3 ± 0.67 µg/mL. The outcome of the MTT assay showed that the extracted guava oil had nearly the same efficacy against breast and liver cancer cells at a low concentration (1 µg/mL), giving 98.3 ± 0.3% and 98.5 ± 0.4% cell viability against HepG2 at 1 µg/mL, respectively. When the concentration of essential oil was increased, it showed a small reduction in the percentage of viable cells. While conducting an in silico study of all the screened compounds, the potential for hydroxycaryophyllene, caryophyllene, caryophyllene oxide, humulene, terpineol, and calamenene to inhibit tumor growth was bolstered due to a resemblance to 4-hydroxytamoxifen, thereby implying that these compounds may act as selective estrogen receptor modulators (SERMs). The ADME analysis of the compounds indicated above revealed that they exhibit excellent drug likeness properties and follow the Lipinski rule of five. Conclusions: Consequently, they have a substantial anticancer therapeutic potential and can be used for novel drug discovery in the effort to minimize the global burden of breast cancer." @default.
• W4308523224 created "2022-11-12" @default.
• W4308523224 creator A5009002257 @default.
• W4308523224 creator A5036017448 @default.
• W4308523224 creator A5037290428 @default.
• W4308523224 creator A5046031055 @default.
• W4308523224 creator A5046522347 @default.
• W4308523224 creator A5048984623 @default.
• W4308523224 creator A5052360804 @default.
• W4308523224 creator A5067088727 @default.
• W4308523224 creator A5076238590 @default.
• W4308523224 creator A5076817559 @default.
• W4308523224 date "2022-11-07" @default.
• W4308523224 modified "2023-09-26" @default.
• W4308523224 title "Guava Leaf Essential Oil as a Potent Antioxidant and Anticancer Agent: Validated through Experimental and Computational Study" @default.
• W4308523224 cites W1527833346 @default.
• W4308523224 cites W1549275022 @default.
• W4308523224 cites W1629950689 @default.
• W4308523224 cites W1974949037 @default.
• W4308523224 cites W1976161355 @default.
• W4308523224 cites W1984042925 @default.
• W4308523224 cites W1985767202 @default.
• W4308523224 cites W1987398734 @default.
• W4308523224 cites W2006420867 @default.
• W4308523224 cites W2007489508 @default.
• W4308523224 cites W2015642465 @default.
• W4308523224 cites W2028691872 @default.
• W4308523224 cites W2036691369 @default.
• W4308523224 cites W2054227402 @default.
• W4308523224 cites W2079801146 @default.
• W4308523224 cites W2084826641 @default.
• W4308523224 cites W2088737448 @default.
• W4308523224 cites W2092736138 @default.
• W4308523224 cites W2100427574 @default.
• W4308523224 cites W2105668062 @default.
• W4308523224 cites W2107108806 @default.
• W4308523224 cites W2111650618 @default.
• W4308523224 cites W2126891371 @default.
• W4308523224 cites W2131457953 @default.
• W4308523224 cites W2134967712 @default.
• W4308523224 cites W2135732933 @default.
• W4308523224 cites W2150607833 @default.
• W4308523224 cites W2158534713 @default.
• W4308523224 cites W2169678694 @default.
• W4308523224 cites W2266845360 @default.
• W4308523224 cites W2528847034 @default.
• W4308523224 cites W2593436234 @default.
• W4308523224 cites W2757527733 @default.
• W4308523224 cites W2887063935 @default.
• W4308523224 cites W2898487653 @default.
• W4308523224 cites W2966626464 @default.
• W4308523224 cites W2968876531 @default.
• W4308523224 cites W3045444181 @default.
• W4308523224 cites W3101013929 @default.
• W4308523224 cites W3113405673 @default.
• W4308523224 cites W3143357176 @default.
• W4308523224 cites W3156085443 @default.
• W4308523224 cites W3174592434 @default.
• W4308523224 cites W3175240465 @default.
• W4308523224 cites W4220947493 @default.
• W4308523224 cites W4248007526 @default.
• W4308523224 cites W4248107770 @default.
• W4308523224 doi "https://doi.org/10.3390/antiox11112204" @default.
• W4308523224 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36358576" @default.
• W4308523224 hasPublicationYear "2022" @default.
• W4308523224 type Work @default.
• W4308523224 citedByCount "4" @default.
• W4308523224 countsByYear W43085232242023 @default.
• W4308523224 crossrefType "journal-article" @default.
• W4308523224 hasAuthorship W4308523224A5009002257 @default.
• W4308523224 hasAuthorship W4308523224A5036017448 @default.
• W4308523224 hasAuthorship W4308523224A5037290428 @default.
• W4308523224 hasAuthorship W4308523224A5046031055 @default.
• W4308523224 hasAuthorship W4308523224A5046522347 @default.
• W4308523224 hasAuthorship W4308523224A5048984623 @default.
• W4308523224 hasAuthorship W4308523224A5052360804 @default.
• W4308523224 hasAuthorship W4308523224A5067088727 @default.
• W4308523224 hasAuthorship W4308523224A5076238590 @default.
• W4308523224 hasAuthorship W4308523224A5076817559 @default.
• W4308523224 hasBestOaLocation W43085232241 @default.
• W4308523224 hasConcept C185592680 @default.
• W4308523224 hasConcept C202751555 @default.
• W4308523224 hasConcept C2777278459 @default.
• W4308523224 hasConcept C2777752497 @default.
• W4308523224 hasConcept C2778004101 @default.
• W4308523224 hasConcept C2778130027 @default.
• W4308523224 hasConcept C2778231731 @default.
• W4308523224 hasConcept C2779788071 @default.
• W4308523224 hasConcept C2780783641 @default.
• W4308523224 hasConcept C2781401929 @default.
• W4308523224 hasConcept C43617362 @default.
• W4308523224 hasConcept C53227056 @default.
• W4308523224 hasConcept C55493867 @default.
• W4308523224 hasConcept C556039675 @default.
• W4308523224 hasConcept C59822182 @default.
• W4308523224 hasConcept C71924100 @default.
• W4308523224 hasConcept C86803240 @default.
• W4308523224 hasConcept C98274493 @default.

• next